Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
58 participants
INTERVENTIONAL
2020-11-23
2022-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy of AP029 Mix in Patients With Impaired Carbohydrate Metabolism
NCT05994586
Glycemic Response to Oral Nutrition Supplements
NCT02612675
Additional Glucose Lowering and Anti-Inflammatory Effects by Acarbose and Alcohol in Subjects With Impaired Glucose Tolerance or Mild Type 2 Diabetes
NCT00417950
Vinegar Co-ingestion in Type 2 Diabetes
NCT01279317
Reduction of the Dietary Glycemic Index (GI) by L-Arabinose and Indigestible Dextrin
NCT01039662
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Research questions:
Does FAE/NFAE when administered to T2D subjects:
* Improve glucose responses to an oral glucose tolerance test and HbA1C?
* Improve fasting LDL-, HDL- and total cholesterol?
* Reduce insulin resistance and increase total antioxidative/anti-inflammatory capacity?
* Increase circulating GLP-1 and GIP levels with lower DPP4 activity?
* Alleviate hypertension and obesity?
Methods A total of 48 T2D patients is needed for the double blind, randomized triple cross-over trial. The patients will consume FAE, NFAE or placebo daily divided into two doses which is expected to provide a sufficient dose of bioactive phenolic compounds. The patients will be recruited through "forsoegsperson.dk", "sundhed.dk", and flyers placed at Aarhus university hospital (AUH). T2D patients with fasting blood glucose ≤ 12 mM and HbA1c \> 6.1% and \< 10%, without severe comorbidities, will be included. Before enrolment, the patients receive all necessary study information (written and oral) including potential adverse effects (e.g. aronia allergy), and they will have to provide their informed consent (visit 1). There will be an assessment of whether the patients fulfill the criteria as well.
The randomized double-blinded triple cross-over study consists of three eight weeks intervention periods (placebo, FAE and NFAE), where the participants are randomly assigned to the order of treatments (six different possibilities of order). The intervention periods are separated by minimum three weeks wash-out periods (see figure 1 for details). Before and after each intervention period, i.e. six times, oral glucose tolerance tests (OGTT) will be performed. The Central Denmark Region Committees on Health Research Ethics has approved the trial.
Analyses OGTT: Prior to the OGTT, the participants have fasted for 8 hours where after they will consume 75 g glucose dissolved in 300 ml water within 5 minutes. Blood will be sampled at time points -10, 0, 30, 60, 90, 120, and 240 minutes.
Blood Analyses: After the blood sampling, plasma will be stored at -80° C until further analysis. Obviously, the investigators aim to determine if FAE and NFAE consumption is capable of lowering the fasting and postprandial blood sugar and thus, the levels of glucose, fructosamin and HbA1c will be measured. The concentration of advanced glycosylation end products will be assessed in fasted blood samples. Also, lipidaemia will be examined, e.g. total cholesterol, triglyceride, high-density lipoprotein and low-density lipoprotein concentrations. The inflammatory state will be assessed by measuring the level of pro- and anti-inflammatory cytokines as well as the concentration of C-reactive protein in fasting blood samples. To determine whether aronia acts through incretin mediated regulation, the concentrations of GIP and GLP-1 and the activity of DDP4 will be measured. The concentrations of glucagon, insulin, and adiponectin will be assessed as well.
Insulin resistance: β-cell dysfunction and insulin resistance will be estimated from blood glucose and insulin concentrations using Homeostasis Model Assessment (3) and Matsuda Index (4) which are based on concentrations measured at fasting states and during the OGTT, respectively.
Diurnal blood pressure: 24-hour ambulatory blood pressure monitoring will be carried out. The necessary equipment is available at AUH. The participants will have their 24-hour blood pressure measured before and after each intervention period.
Body mass index (BMI): At the first visit the participants height and weight are measured, and the weight will subsequently be monitored.
Metabolomics and microbiomics assays: The results from the previous tests (effects on main outcomes) will determine the extent of the subsequent metabolomics and microbiomics analyses. Fecal samples for microbiomics, as well as blood and urine samples for metabolomics will be stored at -80° C until use.
Data analysis: The power calculation is based on our primary effect parameter glucose incremental area under the curve (iAUC). The number of participants needed to obtain a statistical power of 80% at a level of P\<0.05 (α=0.05; 1-β=0.8) was calculated as 48. The investigators wanted to detect a minimal relevant difference for the area of (mean ± s.d.) 65±50 mmol/l x 120 min, which gives us an estimated effect size of 1.30. The anticipated dropout is 20%. ANOVA will be conducted for each variable to determine if the variables change upon administration of FAE, NFAE, or placebo as well as to assess intergroup variability at baseline and endpoint. Significance will be set to p \< 0.05.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fermented aronia - aronia - placebo
The participants receive each intervention for 8 weeks in the stated order.
Fermented aronia
Given twice daily for 8 weeks
Aronia
Given twice daily for 8 weeks
Placebo
Given twice daily for 8 weeks
Fermented aronia - placebo - aronia
The participants receive each intervention for 8 weeks in the stated order.
Fermented aronia
Given twice daily for 8 weeks
Aronia
Given twice daily for 8 weeks
Placebo
Given twice daily for 8 weeks
Placebo - aronia - fermented aronia
The participants receive each intervention for 8 weeks in the stated order.
Fermented aronia
Given twice daily for 8 weeks
Aronia
Given twice daily for 8 weeks
Placebo
Given twice daily for 8 weeks
Placebo - fermented aronia - aronia
The participants receive each intervention for 8 weeks in the stated order.
Fermented aronia
Given twice daily for 8 weeks
Aronia
Given twice daily for 8 weeks
Placebo
Given twice daily for 8 weeks
Aronia - placebo - fermented aronia
The participants receive each intervention for 8 weeks in the stated order.
Fermented aronia
Given twice daily for 8 weeks
Aronia
Given twice daily for 8 weeks
Placebo
Given twice daily for 8 weeks
Aronia - fermented aronia - placebo
The participants receive each intervention for 8 weeks in the stated order.
Fermented aronia
Given twice daily for 8 weeks
Aronia
Given twice daily for 8 weeks
Placebo
Given twice daily for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fermented aronia
Given twice daily for 8 weeks
Aronia
Given twice daily for 8 weeks
Placebo
Given twice daily for 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥30 ≤80 years of age
* Fasting blood glucose ≤12 mmol/liter.
* HbA1c \> 6,1% og \<10%(\>43 og \< 86 mmol/mol) if patients are in medical diabetes treatment
* HbA1c \> 6,5% og \<10% (\>48 og \< 86 mmol/mol) if patients are not in medical diabetes treatment
Exclusion Criteria
* Serious comorbidities, including cardiovascular-, neurological-, psychological- and/or renal diseases.
* Pregnant or planned pregnancy.
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital
Aarhus N, Danmark, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1-10-72-102-19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.